Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) saw a large decrease in short interest in January. As of January 15th, there was short interest totaling 201,697 shares, a decrease of 66.6% from the December 31st total of 603,238 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average daily trading volume, of 454,313 shares, the days-to-cover ratio is currently 0.4 days. Based on an average daily trading volume, of 454,313 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.1% of the company’s stock are sold short.

Hedge Funds Weigh In On Enlivex Therapeutics

Several hedge funds have recently made changes to their positions in the company. Susquehanna International Group LLP purchased a new stake in shares of Enlivex Therapeutics in the 3rd quarter valued at about $57,000. Citizens Financial Group Inc. RI acquired a new position in Enlivex Therapeutics during the third quarter worth approximately $241,000. Finally, Jane Street Group LLC lifted its stake in Enlivex Therapeutics by 527.4% in the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after buying an additional 67,886 shares during the last quarter. Hedge funds and other institutional investors own 1.02% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. D. Boral Capital reaffirmed a “hold” rating on shares of Enlivex Therapeutics in a research report on Monday, November 24th. Wall Street Zen raised Enlivex Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, January 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Enlivex Therapeutics in a report on Monday, December 29th. HC Wainwright lifted their price objective on Enlivex Therapeutics from $7.00 to $13.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Finally, D Boral Capital downgraded Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Enlivex Therapeutics currently has an average rating of “Hold” and a consensus target price of $13.00.

Enlivex Therapeutics Stock Down 7.4%

ENLV traded down $0.09 on Thursday, reaching $1.07. The company’s stock had a trading volume of 327,824 shares, compared to its average volume of 472,406. The stock has a 50 day moving average of $0.92 and a two-hundred day moving average of $1.07. The company has a market capitalization of $252.81 million, a price-to-earnings ratio of -1.94 and a beta of 1.52. Enlivex Therapeutics has a fifty-two week low of $0.66 and a fifty-two week high of $2.10.

Enlivex Therapeutics (NASDAQ:ENLV) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03. As a group, analysts anticipate that Enlivex Therapeutics will post -0.7 earnings per share for the current fiscal year.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.